Oramed Chosen to Lecture at the Fourth International Conference on Advanced Technologies and Treatments for Diabetes in London, England

Chosen to Lecture at the Fourth International Conference on

Technologies and Treatments for Diabetes in London,

Israel - February 15, 2011- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB)

(www.oramed.com), a developer of alternative drug delivery systems, announced

today that its Director of Medical Affairs, Roy Eldor, M.D., was chosen to

lecture at the Fourth International Conference on Advanced Technologies and

Treatments for Diabetes (ATTD) to take place in London, England on February

presentation will be held on February 18, 2011 at 3:30 PM in Hall C at the

Hilton London Metropole. The presentation will be based on the following

abstract: "Continuous monitoring of patients with uncontrolled Type I Diabetes

demonstrated blood glucose reduction upon preprandial administration of

ORMD-0801 insulin capsules".

information please visit the conference website at: http://www2.kenes.com/attd/info/Pages/GeneralInformation.aspx

Oramed Pharmaceuticals

Pharmaceuticals is a technology pioneer in the field of oral delivery solutions

for drugs and vaccines presently delivered via injection. Oramed is seeking

to revolutionize the treatment of diabetes through its patented flagship

product, an orally ingestible insulin capsule currently in phase 2 clinical

trials. Established in 2006, Oramed's technology is based on over 25 years of

research by top research scientists at Jerusalem's Hadassah Medical Center.

Oramed's corporate and R&D headquarters are based in Jerusalem.

information, please visit www.oramed.com.

Some of the statements contained in

this press release are forward-looking statements which involve known and

unknown risks, uncertainties and other factors which may cause the actual

results, performance or achievements of Oramed, or industry results, to be

materially different from any future results, performance or achievements

expressed or implied by such forward looking statements, including the risks and

uncertainties related to the progress, timing, cost, and results of clinical

trials and product development programs; difficulties or delays in obtaining

regulatory approval for our product candidates; competition from other

pharmaceutical or biotechnology companies; and Oramed's ability to obtain

additional funding required to conduct its research, development and

commercialization activities. Please refer to Oramed's filings with the

Securities and Exchange Commission for a comprehensive list of risk factors that

could cause actual results, performance or achievements of Oramed to differ

materially from those expressed or implied in such forward looking statements.

Oramed undertakes no obligation to update or revise any forward-looking

and Investor Relations Contact:

Pharmaceuticals Inc.

Email: tara@oramed.com